A33scFv-cytosine deaminase: a recombinant protein construct for antibody-directed enzyme-prodrug therapy

Br J Cancer. 2003 Mar 24;88(6):937-9. doi: 10.1038/sj.bjc.6600751.

Abstract

A recombinant fusion protein of colon carcinoma binding A33 single chain antibody with cytosine deaminase displayed specific antigen binding and enzyme activity in surface plasmon resonance and is catalytic activity assay. In vitro, it selectively increased the toxicity of 5-FC to A33 antigen-positive cells by 300-fold, demonstrating the potency of this ADEPT strategy.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Antigens, Neoplasm
  • Catalysis
  • Cytosine Deaminase
  • Escherichia coli / genetics
  • Humans
  • Immunoglobulin Fragments
  • Immunoglobulin Variable Region
  • Membrane Glycoproteins / immunology*
  • Membrane Glycoproteins / pharmacology
  • Nucleoside Deaminases / chemistry
  • Nucleoside Deaminases / immunology
  • Nucleoside Deaminases / pharmacology*
  • Polymerase Chain Reaction
  • Recombinant Fusion Proteins / pharmacology*
  • Tumor Cells, Cultured

Substances

  • Antigens, Neoplasm
  • GPA33 protein, human
  • Immunoglobulin Fragments
  • Immunoglobulin Variable Region
  • Membrane Glycoproteins
  • Recombinant Fusion Proteins
  • Nucleoside Deaminases
  • Cytosine Deaminase